The Great Manipulator, page-137

Well done. CSL forms a part of my portfolio, but I am looking to accumulate at the right price. CSL is a high quality addition to any portfolio if you are holding for the long term. I suspect CSL will not fall below a PE of 30 at any point in the next 3-5 years, given the nature of their ongoing R&D portfolio. The factor that sets CSL apart from its peers among the largest five Australian companies - BHP, the Commonwealth Bank, NAB and Westpac is that investors are not buying into it to chase dividend yield. EPS growth will drive future share price appreciation here for at least another 3-5 years. Demand for CSL’s plasma and recombinant products continues to be strong. I'm a buyer below $250.